FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of March 2020
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 

 
 
 
 
AstraZeneca PLC
 
INDEX TO EXHIBITS
 
 
1.
Filing of Form 20-F with SEC
 
 
4 March 2020 07:00 GMT
 
Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission
 
AstraZeneca PLC (the Company) announced today that, on 3 March 2020, it filed its 2019 Annual Report on Form 20-F with the US Securities and Exchange Commission (SEC). The document is available for viewing on the SEC website at www.sec.gov and also on the Company's website at www.astrazeneca.com. The Company will send any holder of the Company's securities, upon request, a hard copy of the Company's complete audited financial statements free of charge. Requests may be made by writing to the Company Secretary, AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK.
 
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
 
Media Relations
 
 
 
Gonzalo Viña
 
 
+44 203 749 5916
 
Rob Skelding
 
Oncology
 
+44 203 749 5821
 
Rebecca Einhorn
 
Oncology
 
+1 301 518 4122
 
Matt Kent
 
BioPharmaceuticals
 
+44 203 749 5906
 
Angela Fiorin
 
BioPharmaceuticals
 
+44 1223 344 690
 
Jennifer Hursit
 
Other
 
+44 203 749 5762
 
Christina Malmberg Hägerstrand
 
Sweden
 
+46 8 552 53 106
 
Michele Meixell
 
US
 
+1 302 885 2677
 
Investor Relations
 
 
 
Thomas Kudsk Larsen
 
 
+44 203 749 5712
 
Henry Wheeler
 
Oncology
 
+44 203 749 5797
 
Christer Gruvris
BioPharmaceuticals
(Cardiovascular, Metabolism)
 
+44 203 749 5711
 
Nick Stone
 
BioPharmaceuticals (Renal) Environmental, Social and Governance
 
+44 203 749 5716
 
Josie Afolabi
 
BioPharmaceuticals (Respiratory)
 
+44 203 749 5631
 
Tom Waldron
 
Other medicines
 
+44 7385 033 717
 
Craig Marks
 
Finance
Fixed income
 
+44 7881 615 764
 
Jennifer Kretzmann
 
Corporate access
Retail investors
 
+44 203 749 5824
 
US toll-free
 
+1 866 381 72 77
 
 
Adrian Kemp
Company Secretary
AstraZeneca PLC
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
 
 
Date: 04 March 2020
 
 
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary